GlaxoSmithKline has begun a COVID-19 clinical trial with China’s Clover Biopharmaceuticals, combining its booster with the biotech’s early-stage vaccine.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.